EGFR and cancer: 8. It is recommended to use skin assessment tools that are easily acceptable to patients, such as Common Terminology Criteria for Adverse Events (CTCAE), Multinational Association of Supportive Care in Cancer (MASCC) Skin Toxicity Scale (MESTT), Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicity Index (EGFRISTI), Dermatology Life Quality Index (DLQI), Skindex, Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18 (FACT-EGFRIs-18) Scale, etc. (14, 18, 20, 26), to assist in determining the grade of cutaneous toxicity (20).